Recombinant escherichia coli for synthesizing violaxanthin and derivatives thereof as well as construction method and application of recombinant escherichia coli
By carrying out multiple genetic modifications to E. coli, the metabolic pathways are optimized, the yield of violetoxin and zeaxanthin is improved, the problem of low yield in the existing technology is solved, and efficient microbial preparation methods are provided, which meets the needs of industrial applications. .
Patent Information
- Application Number
- CN202310732913.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-20
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, purpurin and zeaxanthin have low synthetic yields in microorganisms, which are difficult to meet industrial application needs, and are difficult to extract from plants and have low yields.
Through multiple genetic modifications to E. coli, specific genes were introduced and expressed to enhance the synthesis pathways of violetoxin and zeaxanthin, including importing genes such as mvaS, mvaE, mvk, crrtB, crrtI, crrtE, zep, and knocking out gor , trxB, lpxM, poxB and other genes optimize metabolic pathways to improve yield.
It significantly increases the yield of violetoxin and zeaxanthin, solves the bottleneck problem in industrial production, provides efficient microbial preparation methods, and has a wide range of application prospects.
Smart Images

Figure BDA0004294770300000151
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a recombinant Escherichia coli for synthesizing violaxanthin and its derivatives, and a construction method and application thereof. Background Art
[0002] Carotenoids are one of the most important natural pigments with important physiological functions and multiple potential applications. Xanthophylls are a large class of carotenoids that exist in a variety of organisms and play a particularly important role in light capture and photoprotection in plants and algae. Microbial cell factories are widely used to produce a variety of natural products due to their short production cycle, environmental friendliness, and ability to utilize sustainable resources. The use of metabolically engineered microorganisms to produce carotenoids has attracted much attention as an alternative to current extraction and chemical synthesis processes from natural sources. Metabolic engineering methods have successfully achieved high-yield microorganisms for several important carotenoids, including lycopene, β-carotene, and astaxanthin.
[0003] Violaxanthin is an important plant-derived xanthophyll. Due to its antioxidant activity and bright yellow color, it has potential application value in medicine, food and cosmetics. Violaxanthin is an important carotenoid compound in plants. Violaxanthin is a key precursor of abscisic acid, fucoxanthin and capsanthin, and it participates in the xanthophyll cycle in plants. Violaxanthin is mainly distributed in the leaves, flowers and fruits of ferns, mosses and seed plants. Compared with β-carotene and lutein, violaxanthin has stronger antioxidant capacity. Violaxanthin has also been shown to have anti-cancer, anti-inflammatory and other biological activities. Therefore, violaxanthin has great application value in medicine, food, cosmetics and other products. Due to its low content in plants, it is difficult to obtain it through plant extraction. The use of microorganisms for heterologous synthesis is currently mainly limited by its low synthesis level and is difficult to be used in industrial applications. In Saccharomyces cerevisiae, the yield of violaxanthin is about 7.3 mg / g DCW. In E. coli, the production level of violaxanthin is less than 1 mg / g DCW. Violaxanthin, CAS No. 126-29-4, molecular formula C 40 H 56 O4, molecular weight is 600.87.
[0004] Lutein is also a type of carotenoid, and is widely found in yellow or orange fruits, vegetables, plants, and microalgae in nature. It can participate in the xanthophyll cycle of plants and protect plants from light damage. In addition to being a natural colorant, zeaxanthin also has physiological activities such as antioxidant, anti-cancer, and vision protection, and can be used in food, medical insurance, cosmetics and other fields. The zeaxanthin content in plants is low, and the extraction process from plants is complex and the yield is low. Therefore, the development of microbial heterologous synthesis of zeaxanthin has become a feasible alternative method, but due to its low yield, it cannot be applied to industrial production. Lutein, also known as zeaxanthin, has a CAS No. of 144-68-3 and a molecular formula of C 40 H 56 O2, molecular weight is 568.871. Summary of the invention
[0005] The purpose of the present invention is to provide a recombinant Escherichia coli for synthesizing violaxanthin and its derivatives, and a construction method and application thereof.
[0006] The present invention provides a recombinant Escherichia coli (Escherichia coli A), which is obtained by performing multiple transformations on Escherichia coli.
[0007] The present invention also provides a method for constructing a recombinant Escherichia coli with improved violaxanthin production (method A), comprising the following steps: performing multiple transformations on the Escherichia coli. The Escherichia coli A is the Escherichia coli used for preparing violaxanthin.
[0008] In the Escherichia coli A or the method A: the multiple modifications include modification (a) and / or modification (b) and / or modification (c) and / or modification (e);
[0009] Transformation (a): introduction and expression of mvaS gene, mvaE gene and mvk gene;
[0010] Transformation (b): introducing and expressing crtB gene, crtI gene, crtE gene and idi gene;
[0011] Transformation (c): introduction and expression of zep gene, crtY gene and crtZ gene;
[0012] Transformation (e): Introduction and expression of pmk gene and mvd gene.
[0013] In the Escherichia coli A or the method A: the multiple modifications include modification (a) and modification (b) and modification (c) and modification (e).
[0014] In the Escherichia coli A or the method A: the multiple modifications further include modification (h) and / or modification (i);
[0015] Transformation (h): knocking out the gor gene; Transformation (i): knocking out the trxB gene.
[0016] In the Escherichia coli A or the method A: the multiple modifications include modification (a) and modification (b) and modification (c) and modification (e) and modification (h) and modification (i).
[0017] In the Escherichia coli A or the method A: the multiple modifications further include modification (d);
[0018] Transformation (d): Introduction and expression of fd gene and fnr gene.
[0019] In the Escherichia coli A or the method A: the multiple modifications further include modification (f) and / or modification (g) and / or modification (j);
[0020] Transformation (f): knocking out the lpxM gene; transformation (g): knocking out the poxB gene; transformation (j): knocking out the ldhA gene.
[0021] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (d) and transformation (e) and transformation (h) and transformation (i).
[0022] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (d) and transformation (h) and transformation (i).
[0023] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (d) and transformation (e) and transformation (f) and transformation (g) and transformation (h) and transformation (i) and transformation (j).
[0024] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (d) and transformation (f) and transformation (g) and transformation (h) and transformation (i).
[0025] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (e) and transformation (h) and transformation (i).
[0026] Specifically, the multiple transformations consist of transformation (a), transformation (b), transformation (c), transformation (h), and transformation (i).
[0027] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (e) and transformation (f) and transformation (g) and transformation (h) and transformation (i) and transformation (j).
[0028] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (f) and transformation (g) and transformation (h) and transformation (i).
[0029] Specifically, the multiple transformations consist of transformation (a), transformation (b), transformation (c), and transformation (e).
[0030] Specifically, the multiple transformations consist of transformation (a), transformation (b) and transformation (c).
[0031] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (c) and transformation (e) and transformation (f) and transformation (g) and transformation (j).
[0032] Specifically, the multiple transformations consist of transformation (a), transformation (b), transformation (c), transformation (f), and transformation (g).
[0033] The present invention also protects the use of the Escherichia coli A or the method A in preparing violaxanthin.
[0034] The present invention also protects a recombinant Escherichia coli (Escherichia coli B), which is obtained by performing multiple transformations on Escherichia coli. Escherichia coli B is the Escherichia coli used for preparing zeaxanthin.
[0035] The present invention also protects a method for constructing a recombinant Escherichia coli with improved lutein production (method B), comprising the following steps: performing multiple transformations on the Escherichia coli.
[0036] In the Escherichia coli B or the method B: the multiple modifications include modification (a) and / or modification (b) and / or modification (k) and / or modification (e);
[0037] Transformation (a): introduction and expression of mvaS gene, mvaE gene and mvk gene;
[0038] Transformation (b): introducing and expressing crtB gene, crtI gene, crtE gene and idi gene;
[0039] Transformation (k): introduction and expression of crtY gene and crtZ gene;
[0040] Transformation (e): Introduction and expression of pmk gene and mvd gene.
[0041] In the Escherichia coli B or the method B: the multiple modifications include modification (a) and modification (b) and modification (k) and modification (e).
[0042] In the Escherichia coli B or the method B: the multiple modifications further include modification (h) and / or modification (i);
[0043] Transformation (h): knocking out the gor gene; Transformation (i): knocking out the trxB gene.
[0044] In the Escherichia coli B or the method B: the multiple modifications include modification (a) and modification (b) and modification (k) and modification (e) and modification (h) and modification (i).
[0045] In the Escherichia coli B or the method B: the multiple modifications further include modification (d);
[0046] Transformation (d): Introduction and expression of Fd gene and fnr gene.
[0047] In the Escherichia coli B or the method B: the multiple modifications further include modification (f) and / or modification (g) and / or modification (j);
[0048] Transformation (f): knocking out the lpxM gene; transformation (g): knocking out the poxB gene; transformation (j): knocking out the ldhA gene.
[0049] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (d) and transformation (e) and transformation (h) and transformation (i).
[0050] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (d) and transformation (h) and transformation (i).
[0051] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (d) and transformation (e) and transformation (f) and transformation (g) and transformation (h) and transformation (i) and transformation (j).
[0052] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (d) and transformation (f) and transformation (g) and transformation (h) and transformation (i).
[0053] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (e) and transformation (h) and transformation (i).
[0054] Specifically, the multiple transformations consist of transformation (a), transformation (b), transformation (k), transformation (h), and transformation (i).
[0055] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (e) and transformation (f) and transformation (g) and transformation (h) and transformation (i) and transformation (j).
[0056] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (f) and transformation (g) and transformation (h) and transformation (i).
[0057] Specifically, the multiple transformations consist of transformation (a), transformation (b), transformation (k), and transformation (e).
[0058] Specifically, the multiple transformations consist of transformation (a), transformation (b) and transformation (k).
[0059] Specifically, the multiple transformations consist of transformation (a) and transformation (b) and transformation (k) and transformation (e) and transformation (f) and transformation (g) and transformation (j).
[0060] Specifically, the multiple transformations consist of transformation (a), transformation (b), transformation (k), transformation (f), and transformation (g).
[0061] The present invention also protects the use of the Escherichia coli B or the method B in preparing lutein.
[0062] In any of the above recombinant Escherichia coli or any of the above methods: knocking out the lpxM gene can specifically be knocking out the lpxM gene coding frame.
[0063] In any of the above recombinant Escherichia coli or any of the above methods: knocking out the poxB gene can specifically be knocking out the poxB gene coding frame.
[0064] In any of the above recombinant Escherichia coli or any of the above methods: knocking out the gor gene, specifically, knocking out the gor gene coding frame.
[0065] In any of the above recombinant Escherichia coli or any of the above methods: knocking out the trxB gene can specifically be knocking out the trxB gene coding frame.
[0066] In any of the above recombinant Escherichia coli or any of the above methods: knocking out the ldhA gene can specifically be knocking out the ldhA gene coding frame.
[0067] The lpxM gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 1939222-1940193; the GeneID of the Escherichia coli lpxM gene is 945143, and the encoded protein is shown in GenBank accession number NP_416369.1 (09-MAR-2022).
[0068] The coding frame of the poxB gene is shown in positions 909331-911049 in GenBank accession number NC_000913.3 (09-MAR-2022); the GeneID of the Escherichia coli poxB gene is 946132, and the encoded protein is shown in GenBank accession number NP_415392.1 (09-MAR-2022).
[0069] The gor gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 3646299-3647651; the GeneID of the Escherichia coli Gor gene is 948014, and the encoded protein is shown in GenBank accession number NP_417957.1 (09-MAR-2022). The Gor gene encodes glutathione reductase.
[0070] The trxB gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 931085-932050 (template strand); the GeneID of the Escherichia coli trxB gene is 949054, and the encoded protein is shown in GenBank accession number NP_415408.1 (09-MAR-2022). The trxB gene encodes ferredoxin reductase.
[0071] The coding frame of the ldhA gene is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 1441854-1442843. The GeneID of the Escherichia coli ldhA gene is 946315, and the encoded protein is shown in GenBank accession number NP_415898.1 (09-MAR-2022).
[0072] The transformation (a) may specifically be: integrating the DNA molecules for expressing the mvaS gene, the mvaE gene and the mvk gene into the genomic DNA of Escherichia coli. The integration position may specifically be the lpxM site in the genomic DNA of Escherichia coli. The integration may be achieved by inserting the lpxM gene in the genomic DNA of Escherichia coli, or by replacing the lpxM gene coding frame or a partial segment thereof in the genomic DNA of Escherichia coli.
[0073] Transformation (a) and transformation (f) can be accomplished simultaneously, namely, replacing the lpxM gene coding frame in the E. coli genomic DNA with a DNA molecule for expressing the mvaS gene, the mvaE gene and the mvk gene.
[0074] The DNA molecule used to express the mvaS gene, the mvaE gene and the mvk gene can be specifically the MV fragment. The MV fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: Kan residual segment, ParaBAD promoter, mvaS gene, RBS1, mvaE gene, RBS1, mvk gene and TrrnB terminator.
[0075] The transformation (a) and the transformation (f) are specifically realized by using the LP-MV fragment, the pKD46 plasmid and the pCP20 plasmid. The LP-MV fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: the lpxMup segment, the Kan-related segment, the ParaBAD promoter, the mvaS gene, RBS1, the mvaE gene, RBS1, the mvk gene, the TrrnB terminator and the lpxMdown segment.
[0076] The transformation (b) may specifically be: integrating the DNA molecules for expressing the crtB gene, crtI gene, crtE gene and idi gene into the genomic DNA of Escherichia coli. The integration position may specifically be the poxB site in the genomic DNA of Escherichia coli. The integration may be achieved by inserting the poxB gene in the genomic DNA of Escherichia coli, or by replacing the poxB gene coding frame or a partial segment thereof in the genomic DNA of Escherichia coli.
[0077] Transformation (b) and transformation (g) can be accomplished simultaneously, namely, replacing the poxB gene coding frame in the E. coli genomic DNA with a DNA molecule for expressing the crtB gene, crtI gene, crtE gene and idi gene.
[0078] The DNA molecule used to express crtB gene, crtI gene, crtE gene and idi gene can be specifically a CT fragment. The CT fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: Kan residual segment, Ptac promoter, RBS2, crtB gene, RBS3, crtI gene, RBS4, crtE gene, RBS5, idi gene and Tl3 terminator.
[0079] The transformation (b) and transformation (g) are specifically achieved using the PX-CT fragment, pKD46 plasmid and pCP20 plasmid. The PX-CT fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: poxBup segment, Kan-related segment, Ptac promoter, RBS2, crtB gene, RBS3, crtI gene, RBS4, crtE gene, RBS5, idi gene, Tl3 terminator and poxBdown segment.
[0080] The transformation (c) may specifically be: introducing a DNA molecule for expressing the zep gene, the crtY gene and the crtZ gene or a recombinant expression vector having the DNA molecule into Escherichia coli.
[0081] The DNA molecule used to express the zep gene, the crtY gene and the crtZ gene can be specifically the YZZ segment. The YZZ segment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: D0 regulatory element, zep gene, D1 regulatory element, crtY gene, D2 regulatory element, crtZ gene and TrrnB terminator. The recombinant expression vector with the YZZ segment can be specifically the recombinant plasmid pS-YZZ. The recombinant plasmid pS-YZZ is a circular plasmid composed of double-stranded DNA molecules, which is composed of the following two segments: the YZZ segment and the pS segment.
[0082] The transformation (k) may specifically be: introducing a DNA molecule for expressing the crtY gene and the crtZ gene or a recombinant expression vector having the DNA molecule into Escherichia coli.
[0083] The DNA molecule used to express the crtY gene and the crtZ gene can be specifically the YZ segment. The YZ segment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: D1 regulatory element, crtY gene, D2 regulatory element, crtZ gene and TrrnB terminator. The recombinant expression vector with the YZ segment can be specifically the recombinant plasmid pS-YZ. The recombinant plasmid pS-YZ is a circular plasmid composed of double-stranded DNA molecules, which is composed of the following two segments: YZ segment and pS segment.
[0084] The transformation (d) may specifically be: introducing a DNA molecule for expressing the fd gene and the fnr gene or a recombinant expression vector having the DNA molecule into Escherichia coli.
[0085] The DNA molecule used to express the fd gene and the fnr gene can be specifically a CtrFd-Fnr fragment. The CtrFd-Fnr fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: RBS6, fd gene, RBS6, fnr gene and TrrnB terminator. The recombinant expression vector with the CtrFd-Fnr fragment can be specifically a recombinant plasmid pL-FDN. The recombinant plasmid pL-FDN is a circular plasmid composed of double-stranded DNA molecules, which is composed of the following two segments: the CtrFd-Fnr fragment and the pL fragment.
[0086] Transformation (h), i.e., replacing the gor gene coding frame in the E. coli genomic DNA with the Kan residual segment.
[0087] The transformation (h) is specifically achieved using Kan-G fragment, pKD46 plasmid and pCP20 plasmid. The Kan-G fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: Gorup segment, Kan-related segment and Gordown segment.
[0088] Transformation (i), namely: replacing the trxB gene coding frame in the E. coli genomic DNA with the Kan residual segment.
[0089] The transformation (i) is specifically achieved using Kan-T fragment, pKD46 plasmid and pCP20 plasmid. The Kan-T fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: TrxBup fragment, Kan-related segment, TrxBdown fragment.
[0090] The transformation (e) may specifically be: integrating the DNA molecules for expressing the pmk gene and the mvd gene into the genomic DNA of Escherichia coli. The integration position may specifically be the ldhA site in the genomic DNA of Escherichia coli. The integration may be achieved by inserting the ldhA gene in the genomic DNA of Escherichia coli, or by replacing the ldhA gene coding frame or a partial segment thereof in the genomic DNA of Escherichia coli.
[0091] Transformation (e) and transformation (j) can be accomplished simultaneously, namely, replacing the ldhA gene coding frame in the E. coli genomic DNA with a DNA molecule for expressing the pmk gene and the mvd gene.
[0092] The DNA molecule used to express the pmk gene and the mvd gene can be specifically a pmk-mvd fragment. The pmk-mvd fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: P119 promoter, RBS1, pmk gene, RBS1, mvd gene and TrrnB terminator.
[0093] The P119 promoter is shown in SEQ ID NO: 1. RBS1 is shown in SEQ ID NO: 2. The TrrnB terminator is shown in SEQ ID NO: 3. The LpxMup segment is shown in SEQ ID NO: 4. The lpxMdown segment is shown in SEQ ID NO: 5. The Kan-related segment is shown in SEQ ID NO: 6. The ParaBAD promoter is shown in SEQ ID NO: 7. The poxBup segment is shown in SEQ ID NO: 8. The poxBdown segment is shown in SEQ ID NO: 9. The Ptac promoter is shown in SEQ ID NO: 10. The Tl3 terminator is shown in SEQ ID NO: 11. RBS2 is shown in SEQ ID NO: 12. RBS3 is shown in SEQ ID NO: 13. RBS4 is shown in SEQ ID NO: 14. RBS5 is shown in SEQ ID NO: 15. The D0 regulatory element is shown in SEQ ID NO: 16. The D1 regulatory element is shown in SEQ ID NO: 17. The D2 regulatory element is shown in SEQ ID NO: 18. The pS fragment is a double-stranded DNA molecule, as shown in SEQ ID NO: 19. The Gorup fragment is shown in SEQ ID NO: 20. The Gordown fragment is shown in SEQ ID NO: 21. The TrxBup fragment is shown in SEQ ID NO: 22. The TrxBdown fragment is shown in SEQ ID NO: 23. RBS6 is shown in SEQ ID NO: 24. The pL fragment is a double-stranded DNA molecule, as shown in SEQ ID NO: 25. The Kan residual segment is shown in SEQ ID NO: 26.
[0094] The pmk gene is shown in GenBank accession number NM_001182727.1 (13-JAN-2023); the protein encoded by the pmk gene is shown in GenBank accession number NP_013947.1 (13-JAN-2023), which is derived from Saccharomyces cerevisiae. The pmk gene encodes mevalonate phosphokinase.
[0095] The mvd gene is shown in GenBank accession number NM_001183220.1 (13-JAN-2023); the protein encoded by the mvd gene is shown in GenBank accession number NP_014441.1 (13-JAN-2023), which is derived from Saccharomyces cerevisiae. The mvd gene encodes mevalonate decarboxylase.
[0096] The mvaS gene is shown in GenBank accession number AF290092.1 (29-AUG-2000) at positions 142-1293; the protein encoded by the mvaS gene is shown in GenBank accession number AAG02438.1 (29-AUG-2000), which is derived from Enterococcus faecalis. The mvaS gene encodes 3-hydroxy-3-methylglutaryl-CoA synthetase.
[0097] The mvaE gene is shown in GenBank accession number AF290092.1 (29-AUG-2000) at positions 1479-3890; the protein encoded by the mvaE gene is shown in GenBank accession number AAG02439.1 (29-AUG-2000), which is derived from Enterococcus faecalis. The mvaE gene encodes acetyl-CoA acetyltransferase.
[0098] The mvk gene is shown in GenBank accession number MH084473.1 (14-JAN-2019) at positions 1-906; the protein encoded by the mvk gene is shown in GenBank accession number AZW07554.1 (14-JAN-2019). The mvk gene encodes mevalonate kinase.
[0099] The crtB gene is shown in GenBank accession number D90087.2 (05-AUG-2008) at positions 5057-5986; the protein encoded by the crtB gene is shown in GenBank accession number BAA14128.2 (05-AUG-2008), which is derived from Pantoea ananatis. The crtB gene encodes phytoene synthase.
[0100] The crtI gene is shown in GenBank accession number D90087.2 (05-AUG-2008) at positions 3582-5060; the protein encoded by the crtI gene is shown in GenBank accession number BAA14127.1 (05-AUG-2008), which is derived from Pantoea ananatis. The crtI gene encodes phytoene dehydrogenase.
[0101] The crtE gene is shown in GenBank accession number D90087.2 (05-AUG-2008) at positions 225-1133; the protein encoded by the crtE gene is shown in GenBank accession number BAA14124.1 (05-AUG-2008), and is derived from Pantoea ananatis. The crtE gene encodes geranylgeranyl pyrophosphate synthase.
[0102] The idi gene is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 3033065-3033613; the protein encoded by the idi gene is shown in GenBank accession number NP_417365.1 (09-MAR-2022), which is derived from Escherichia coli.
[0103] The zep gene is shown in GenBank accession number XM_047407391.1 (05-APR-2022) at positions 408-2393; the protein encoded by the zep gene is shown in GenBank accession number XP_047263347.1 (05-APR-2022), which is derived from Capsicum annuum. The zep gene encodes zeaxanthin epoxidase.
[0104] The crtY gene is shown in GenBank accession number CP077368.1 (28-JUN-2021) at positions 191390-192550; the protein encoded by the crtY gene is shown in GenBank accession number QXB60949.1 (28-JUN-2021), which is derived from Pantoea agglomerans. The crtY gene encodes lycopene β-cyclase.
[0105] The crtZ gene is shown in GenBank accession number HQ003247.1 (09-JAN-2011) at positions 111-638; the protein encoded by the crtZ gene is shown in GenBank accession number ADU76136.1 (09-JAN-2011), which is derived from Pantoea agglomerans. The crtZ gene encodes β-carotene hydroxylase.
[0106] The fd gene is shown in GenBank accession number AE006470.1 (31-JAN-2014) at positions 1184476-1184664; the protein encoded by the fd gene is shown in GenBank accession number AAM72491.1 (31-JAN-2014), which is derived from Chlorobaculum[tepidum.
[0107] The fnr gene is shown in GenBank accession number AE006470.1 (31-JAN-2014) at positions 1418760-1419842; the protein encoded by the fnr gene is shown in GenBank accession number AAM72739.1 (31-JAN-2014), which is derived from Chlorobaculum[tepidum.
[0108] The protein encoded by the fd gene and the protein encoded by the fnr gene belong to ferredoxin-FNR (ferredoxin: NADP + oxidoreductase) electron transfer system.
[0109] The Escherichia coli may specifically be Escherichia coli G01 or Escherichia coli BW25113.
[0110] The biosynthesis of violaxanthin requires the universal carotenoid precursors isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), which are provided by the mevalonate (MVA) pathway or the methylerythritol 4-phosphate (MEP) pathway. The condensation of IPP and DMAPP leads to the formation of the intermediate farnesyl diphosphate (FPP, C15). Lycopene is biosynthesized from farnesyl diphosphate as a precursor through sequential reactions catalyzed by farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS, CrtE), phytoene synthase (PSY, CrtB), and phytoene desaturase (PDS, CrtI). The synthesis of violaxanthin from lycopene requires three additional steps. Lycopene is first cyclized by lycopene β-cyclase (LCYB, CrtY) to form β-carotene, which is then converted to zeaxanthin by β-carotene 3-hydroxylase (CHYB, CrtZ). Violaxanthin is finally oxidized by zeaxanthin epoxidase (ZEP) to form zeaxanthin.
[0111] The present invention prepares recombinant Escherichia coli capable of producing violaxanthin and zeaxanthin in high yield, improves the yield of target substances while reducing the yield of by-products, solves the bottleneck problem in the industrial production of the two substances, can be used for mass production of violaxanthin and zeaxanthin industries and downstream derivative industries, and has great application and promotion prospects. DETAILED DESCRIPTION
[0112] The present invention is further described in detail below in conjunction with specific embodiments. The examples given are only for illustrating the present invention, not for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources. Unless otherwise specified, the quantitative tests in the following examples are all set up for three repeated experiments, and the results are averaged. pKD46 plasmid: Escherichia coli Genetic Collection Center, Yale University, USA CGSC. pCP20 plasmid: Escherichia coli Genetic Collection Center, Yale University, USA CGSC. In the examples, the same element name corresponds to the same nucleotide sequence, and the nucleotide sequence is described accordingly only when it appears for the first time. Liquid LB medium (pH 7.0): containing 1g / 100mL NaCl, 1g / 100mL tryptone, 0.5g / 100mL yeast powder, and the balance is water. Solid culture medium is obtained by adding agarose to liquid culture medium. Transformation medium (pH7.0): contains 25mM Na2HPO4, 25mM KH2PO4, 20g / 100mL D-glucose, and the balance is water. pKD46 plasmid: contains temperature-sensitive replication origin oriR101, which can replicate normally when cultured at 30°C, and will be automatically lost when cultured above 37°C; Escherichia coli carrying PKD46 plasmid is cultured at 30°C, and Gam, Exo and Beta are efficiently expressed after adding arabinose induction. Once exogenous dsDNA is electroporated into the cell, it can undergo homologous recombination with the genomic target sequence; it carries the ampicillin resistance gene as a screening marker. pCP20 plasmid: Escherichia coli carrying the pCP20 plasmid can express the flippase recombinase (FLP) gene when cultured at 30°C, eliminating a FRT site and the kanamycin resistance gene; Escherichia coli carrying the pCP20 plasmid will automatically lose the pCP20 plasmid when cultured at 42°C; it carries the ampicillin resistance gene as a screening marker.
[0113] Escherichia coli BW25113 has been sequenced and verified, and its genomic DNA has the following segments: the ldhA gene coding frame shown at positions 1441854-1442843 in GenBank accession number NC_000913.3; the lpxM gene coding frame shown at positions 1939222-1940193 in GenBank accession number NC_000913.3, and its upstream and downstream sequences (positions 1940693-1940194 in GenBank accession number NC_000913.3, positions 1939221-1938722 in GenBank accession number NC_000913.3); the poxB gene coding frame shown at positions 909331-911049 in GenBank accession number NC_000913.3, and its upstream and downstream sequences (GenBank accession number NC_000913.3). number NC_000913.3, 911549-911050, and 909330-908831 in GenBank accession number NC_000913.3); the gor gene coding frame and its upstream and downstream 70 bp each as shown in the 3646299-3647651 positions in GenBank accession number NC_000913.3; the trxB gene coding frame and its upstream and downstream 70 bp each as shown in the 931085-932050 positions in GenBank accession number NC_000913.3. The corresponding date of GenBank accession number NC_000913.3 is 09-MAR-2022.
[0114] Example 1. Construction of recombinant Escherichia coli
[0115] 1. Obtaining Escherichia coli G01
[0116] The ldhA gene coding frame (coding chain) in the genomic DNA of Escherichia coli BW25113 was replaced with the pmk-mvd fragment, while the other parts remained unchanged, to obtain a recombinant Escherichia coli, namely Escherichia coli G01.
[0117] The ldhA gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 1441854-1442843 (template strand). The GeneID of the Escherichia coli ldhA gene is 946315, and the encoded protein is shown in GenBank accession number NP_415898.1 (09-MAR-2022).
[0118] The pmk-mvd fragment is a double-stranded DNA molecule, which consists of the following segments from upstream to downstream: P119 promoter, RBS1, pmk gene, RBS1, mvd gene and TrrnB terminator. The P119 promoter is shown in SEQ ID NO: 1. RBS1 is shown in SEQ ID NO: 2. The TrrnB terminator is shown in SEQ ID NO: 3. The pmk gene is shown in GenBank accession number NM_001182727.1 (13-JAN-2023); the protein encoded by the pmk gene is shown in GenBank accession number NP_013947.1 (13-JAN-2023), which is derived from Saccharomyces cerevisiae. The mvd gene is shown in GenBank accession number NM_001183220.1 (13-JAN-2023); the protein encoded by the mvd gene is shown in GenBank accession number NP_014441.1 (13-JAN-2023), which is derived from Saccharomyces cerevisiae.
[0119] Escherichia coli G01 is recorded in the following document (i.e., “strain G01” in the document): Na Liu, Bo Liu, Gaoyan Wang, Ya-Hue Valerie Soong, Yong Tao, Weifeng Liu, Dongming Xie. Lycopene production from glucose, fatty acid and waste cooking oil by metabolically engineered Escherichia coli. Biochemical Engineering Journal 155(2020)107488.
[0120] 2. Construction of E. coli V01
[0121] 1. Prepare LP-MV fragments (LP-MV fragments are used as targeting fragments).
[0122] The LP-MV fragment is a double-stranded DNA molecule, which consists of the following segments from upstream to downstream: lpxMup segment, Kan-related segment, ParaBAD promoter, mvaS gene, RBS1, mvaE gene, RBS1, mvk gene, TrrnB terminator and lpxMdown segment.
[0123] The LpxMup segment is shown in SEQ ID NO: 4, which is the reverse complementary sequence of positions 1940693-1940194 in GenBank accession number NC_000913.3 (09-MAR-2022). The lpxMdown segment is shown in SEQ ID NO: 5, which is the reverse complementary sequence of positions 1939221-1938722 in GenBank accession number NC_000913.3 (09-MAR-2022). The Kan-related segment is shown in SEQ ID NO: 6, which corresponds to positions 31-1509 in GenBank accession number AY048743.1 (11-SEP-2001) (positions 459-1253 in AY048743.1 are kanamycin resistance genes). The ParaBAD promoter is shown in SEQ ID NO: 7, corresponding to positions 68-1372 in GenBank accession number AY842513.1 (28-DEC-2004). The mvaS gene is shown in GenBank accession number AF290092.1 (29-AUG-2000), positions 142-1293; the protein encoded by the mvaS gene is shown in GenBank accession number AAG02438.1 (29-AUG-2000), which is derived from Enterococcus faecalis. The mvaE gene is shown in GenBank accession number AF290092.1 (29-AUG-2000), positions 1479-3890; the protein encoded by the mvaE gene is shown in GenBank accession number AAG02439.1 (29-AUG-2000), which is derived from Enterococcus faecalis. The mvk gene is shown in GenBank accession number MH084473.1 (14-JAN-2019), positions 1-906; the protein encoded by the mvk gene is shown in GenBank accession number AZW07554.1 (14-JAN-2019).
[0124] 2. The pKD46 plasmid was transformed into E. coli G01 competent cells by the calcium chloride transformation method, cultured overnight at 30°C on a solid LB medium plate containing 100 μg / ml ampicillin, and then a single clone was selected to obtain a recombinant E. coli carrying the pKD46 plasmid, named G01 / pKD46.
[0125] 3. The LP-MV fragment was electrotransfected into G01 / pKD46 competent cells, cultured overnight at 37°C on a solid LB medium plate containing 50μg / ml kanamycin, and a single clone was selected. The genomic DNA was extracted and PCR amplified using a primer pair consisting of LP-0 and Kan-R. The positive single clone that amplified a target band of about 1300bp was named V01-kan. The sequencing results showed that the LP-MV fragment had been integrated into the genomic DNA of V01-kan.
[0126] 4. Inoculate V01-kan onto a solid LB medium plate, culture at 42°C overnight, then pick a single clone and prepare competent cells.
[0127] 5. The pCP20 plasmid was transformed into the competent cells obtained in step 4 by the calcium chloride transformation method, cultured on a solid LB medium plate containing 100 μg / ml ampicillin at 30°C overnight, and then a single clone was picked.
[0128] 6. The single clone obtained in step 5 was inoculated onto a solid LB medium plate, cultured at 42°C overnight, and then a single clone was picked and inoculated onto a solid LB medium plate for propagation.
[0129] 7. Pick the strain from the plate in step 6, extract the genomic DNA and perform PCR amplification using the primer pair consisting of LP-0 and mvaS-1. The recombinant E. coli with a target band of about 1300 bp is named E. coli V01.
[0130] 8. Sequencing verification showed that the only difference between the genomic DNA of E. coli V01 and that of E. coli G01 was that the lpxM gene coding frame (coding chain) was replaced with the MV fragment. The lpxM gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 1939222-1940193 (template chain); the GeneID of the E. coli lpxM gene is 945143, and the encoded protein is shown in GenBank accession number NP_416369.1 (09-MAR-2022). The MV fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: Kan residual segment, ParaBAD promoter, mvaS gene, RBS1, mvaE gene, RBS1, mvk gene and TrrnB terminator. The Kan residual segment is shown in SEQ ID NO: 26.
[0131] 3. Construction of E. coli V02
[0132] 1. Prepare PX-CT fragment (PX-CT fragment is used as targeting fragment).
[0133] The PX-CT fragment is a double-stranded DNA molecule, which consists of the following segments from upstream to downstream: poxBup segment, Kan-related segment, Ptac promoter, RBS2, crtB gene, RBS3, crtI gene, RBS4, crtE gene, RBS5, idi gene, Tl3 terminator and poxBdown segment.
[0134] The poxBup segment is shown in SEQ ID NO: 8, which is the reverse complementary sequence of positions 911549-911050 in GenBank accession number NC_000913.3 (09-MAR-2022). The poxBdown segment is shown in SEQ ID NO: 9, which is the reverse complementary sequence of positions 909330-908831 in GenBank accession number NC_000913.3 (09-MAR-2022). The Ptac promoter is shown in SEQ ID NO: 10, corresponding to positions 3302-3363 in GenBank accession number MG323874.1 (19-JUN-2018). The Tl3 terminator is shown in SEQ ID NO: 11, corresponding to positions 1140-1411 in GenBank accession number MH614589.1 (19-FEB-2019). RBS2 is shown in SEQ ID NO: 12. RBS3 is shown in SEQ ID NO: 13. RBS4 is shown in SEQ ID NO: 14. RBS5 is shown in SEQ ID NO: 15. The crtB gene is shown in GenBank accession number D90087.2 (05-AUG-2008) at positions 5057-5986; the protein encoded by the crtB gene is shown in GenBank accession number BAA14128.2 (05-AUG-2008), which is derived from Pantoea ananatis. The crtI gene is shown in GenBank accession number D90087.2 (05-AUG-2008) at positions 3582-5060; the protein encoded by the crtI gene is shown in GenBank accession number BAA14127.1 (05-AUG-2008), which is derived from Pantoea ananatis. The crtE gene is shown in GenBank accession number D90087.2 (05-AUG-2008) at positions 225-1133; the protein encoded by the crtE gene is shown in GenBank accession number BAA14124.1 (05-AUG-2008), and is derived from Pantoea ananatis.The idi gene is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 3033065-3033613; the protein encoded by the idi gene is shown in GenBank accession number NP_417365.1 (09-MAR-2022), which is derived from Escherichia coli.
[0135] 2. The pKD46 plasmid was transformed into E. coli V01 competent cells by the calcium chloride transformation method, cultured overnight at 30°C on a solid LB medium plate containing 100 μg / ml ampicillin, and then a single clone was selected to obtain a recombinant E. coli carrying the pKD46 plasmid, named V01 / pKD46.
[0136] 3. The PX-CT fragment was electrotransfected into V01 / pKD46 competent cells, cultured overnight at 37°C on a solid LB medium plate containing 50μg / ml kanamycin, and a single clone was selected. The genomic DNA was extracted and PCR amplified using a primer pair consisting of PX-0 and Kan-R. The positive single clone that amplified a target band of about 1300bp was named V02-kan. The sequencing results showed that the PX-CT fragment had been integrated into the genomic DNA of V02-kan.
[0137] 4. Inoculate V02-kan onto a solid LB medium plate, culture at 42°C overnight, then pick a single clone and prepare competent cells.
[0138] 5. The pCP20 plasmid was transformed into the competent cells obtained in step 4 by the calcium chloride transformation method, cultured on a solid LB medium plate containing 100 μg / ml ampicillin at 30°C overnight, and then a single clone was picked.
[0139] 6. The single clone obtained in step 5 was inoculated onto a solid LB medium plate, cultured at 42°C overnight, and then a single clone was picked and inoculated onto a solid LB medium plate for propagation.
[0140] 7. Pick the strain from the plate in step 6, extract the genomic DNA and use the primer pair consisting of PX-0 and crtE-1 to perform PCR amplification and identification. The recombinant E. coli with a target band of about 2000 bp is named E. coli V02.
[0141] 8. Sequencing verification showed that the only difference between the genomic DNA of E. coli V02 and that of E. coli V01 was that the poxB gene coding frame (coding chain) was replaced by the CT fragment. The poxB gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 909331-911049 (template chain); the GeneID of the E. coli poxB gene is 946132, and the encoded protein is shown in GenBank accession number NP_415392.1 (09-MAR-2022). The CT fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: Kan residual segment, Ptac promoter, RBS2, crtB gene, RBS3, crtI gene, RBS4, crtE gene, RBS5, idi gene and Tl3 terminator.
[0142] 4. Construction of recombinant plasmids pS-YZZ and pS-YZZC
[0143] 1. Prepare YZZ fragment.
[0144] The YZZ fragment is a double-stranded DNA molecule, which consists of the following segments from upstream to downstream: D0 regulatory element, zep gene, D1 regulatory element, crtY gene, D2 regulatory element, crtZ gene and TrrnB terminator.
[0145] The D0 regulatory element is shown in SEQ ID NO: 16. The D1 regulatory element is shown in SEQ ID NO: 17. The D2 regulatory element is shown in SEQ ID NO: 18. The zep gene is shown in GenBank accession number XM_047407391.1 (05-APR-2022) at positions 408-2393; the protein encoded by the zep gene is shown in GenBank accession number XP_047263347.1 (05-APR-2022), which is derived from Capsicum[annuum. The crtY gene is shown in GenBank accession number CP077368.1 (28-JUN-2021) at positions 191390-192550; the protein encoded by the crtY gene is shown in GenBank accession number QXB60949.1 (28-JUN-2021), which is derived from Pantoea agglomerans. The crtZ gene is shown in GenBank accession number HQ003247.1 (09-JAN-2011), positions 111-638; the protein encoded by the crtZ gene is shown in GenBank accession number ADU76136.1 (09-JAN-2011), and is derived from Pantoea agglomerans.
[0146] 2. Prepare YZZC fragment.
[0147] The YZZC fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: D0 regulatory element, zep gene, D0 regulatory element, crtY gene, D0 regulatory element, crtZ gene and TrrnB terminator.
[0148] 3. Prepare pS fragment (as vector backbone).
[0149] The pS fragment is a double-stranded DNA molecule, as shown in SEQ ID NO: 19. In SEQ ID NO: 19, positions 214-670 are the replication initiation site rep, positions 594-1544 encode the replication initiation site repA protein, and positions 2159-2950 encode the streptomycin resistance protein.
[0150] 4. Prepare the recombinant plasmid pS-YZZ.
[0151] The recombinant plasmid pS-YZZ is a double-stranded DNA circular plasmid consisting of the following two segments: the YZZ segment and the pS segment.
[0152] 5. Prepare the recombinant plasmid pS-YZZC.
[0153] The recombinant plasmid pS-YZZC is a double-stranded DNA circular plasmid, which consists of the following two segments: YZZC segment and pS segment.
[0154] 5. Construction of E. coli V03
[0155] 1. Prepare Kan-G fragment.
[0156] The Kan-G fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: Gorup segment, Kan-related segment and Gordown segment.
[0157] The Gorup fragment is shown as SEQ ID NO: 20. The Gordown fragment is shown as SEQ ID NO: 21.
[0158] 2. The pKD46 plasmid was transformed into E. coli V02 competent cells by the calcium chloride transformation method, cultured overnight at 30°C on a solid LB medium plate containing 100 μg / ml ampicillin, and then a single clone was selected to obtain a recombinant E. coli carrying the pKD46 plasmid, named V02 / pKD46.
[0159] 3. The Kan-G fragment was electrotransfected into V02 / pKD46 competent cells, cultured overnight at 37°C on a solid LB medium plate containing 50μg / ml kanamycin, and single clones were selected. Genomic DNA was extracted and PCR amplified using a primer pair consisting of GOR-0 and Kan-R. The positive single clone that amplified a target band of about 1300bp was named V03-kan. Sequencing results showed that the Kan-G fragment had been integrated into the genomic DNA of V03-kan.
[0160] 4. Inoculate V03-kan onto a solid LB medium plate, culture at 42°C overnight, then pick a single clone and prepare competent cells.
[0161] 5. The pCP20 plasmid was transformed into the competent cells obtained in step 4 by the calcium chloride transformation method, cultured on a solid LB medium plate containing 100 μg / ml ampicillin at 30°C overnight, and then a single clone was picked.
[0162] 6. The single clone obtained in step 5 was inoculated onto a solid LB medium plate, cultured at 42°C overnight, and then a single clone was picked and inoculated onto a solid LB medium plate for propagation.
[0163] 7. Pick the strain from the plate in step 6, extract the genomic DNA and perform PCR amplification using the primer pair consisting of GOR-0 and Kan-G2. The recombinant E. coli with a target band of about 200 bp is named E. coli V03.
[0164] 8. Sequencing confirmed that the only difference between the genomic DNA of E. coli V03 and that of E. coli V02 is that the gor gene coding frame (coding chain) is replaced by the Kan residual segment. The gor gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 3646299-3647651 (coding chain); the GeneID of the E. coli gor gene is 948014, and the encoded protein is shown in GenBank accession number NP_417957.1 (09-MAR-2022).
[0165] VI. Construction of E. coli V04
[0166] 1. Preparation of Kan-T fragment.
[0167] The Kan-T fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: TrxBup fragment, Kan-related segment, and TrxBdown fragment.
[0168] The TrxBup fragment is shown in SEQ ID NO: 22. The TrxBdown fragment is shown in SEQ ID NO: 23.
[0169] 2. The pKD46 plasmid was transformed into E. coli V03 competent cells by the calcium chloride transformation method, cultured overnight at 30°C on a solid LB medium plate containing 100 μg / ml ampicillin, and then a single clone was selected to obtain a recombinant E. coli carrying the pKD46 plasmid, named V03 / pKD46.
[0170] 3. The Kan-T fragment was electrotransfected into V03 / pKD46 competent cells, cultured overnight at 37°C on a solid LB medium plate containing 50μg / ml kanamycin, and single clones were selected. Genomic DNA was extracted and PCR amplified using a primer pair consisting of TRX-0 and Kan-R. The positive single clone that amplified a target band of about 1300bp was named V04-kan. Sequencing results showed that the Kan-T fragment had been integrated into the genomic DNA of V04-kan.
[0171] 4. Inoculate V04-kan onto a solid LB medium plate, culture at 42°C overnight, then pick a single clone and prepare competent cells.
[0172] 5. The pCP20 plasmid was transformed into the competent cells obtained in step 4 by the calcium chloride transformation method, cultured on a solid LB medium plate containing 100 μg / ml ampicillin at 30°C overnight, and then a single clone was picked.
[0173] 6. The single clone obtained in step 5 was inoculated onto a solid LB medium plate, cultured at 42°C overnight, and then a single clone was picked and inoculated onto a solid LB medium plate for propagation.
[0174] 7. Pick the strain from the plate in step 6, extract the genomic DNA and perform PCR amplification using the primer pair consisting of TRX-0 and Kan-T2. The recombinant E. coli with a target band of about 200 bp is named E. coli V04.
[0175] The sequencing results showed that the only difference between the genomic DNA of E. coli V04 and that of E. coli V03 was that the trxB gene coding frame (coding strand) was replaced by the Kan residual segment. The trxB gene coding frame is shown in GenBank accession number NC_000913.3 (09-MAR-2022) at positions 931085-932050 (template strand); the GeneID of the E. coli trxB gene is 949054, and the encoded protein is shown in GenBank accession number NP_415408.1 (09-MAR-2022).
[0176] VII. Construction of recombinant plasmid pL-FDN
[0177] 1. Prepare CtrFd-Fnr fragment.
[0178] The CtrFd-Fnr fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: RBS6, fd gene, RBS6, fnr gene and TrrnB terminator.
[0179] RBS6 is shown in SEQ ID NO: 24. The fd gene is shown in GenBank accession number AE006470.1 (31-JAN-2014) at positions 1184476-1184664; the protein encoded by the fd gene is shown in GenBank accession number AAM72491.1 (31-JAN-2014), which is derived from Chlorobaculum[tepidum. The fnr gene is shown in GenBank accession number AE006470.1 (31-JAN-2014) at positions 1418760-1419842; the protein encoded by the fnr gene is shown in GenBank accession number AAM72739.1 (31-JAN-2014), which is derived from Chlorobaculum[tepidum.
[0180] 2. Prepare pL fragment (as vector backbone).
[0181] The pL fragment is a double-stranded DNA molecule, as shown in SEQ ID NO: 25. In SEQ ID NO: 25, positions 16-402 are replication initiation site r6k, positions 492-1409 encode replication initiation site pir protein, and positions 1669-2484 encode kanamycin resistance protein.
[0182] 3. Prepare the recombinant plasmid pL-FDN.
[0183] The recombinant plasmid pL-FDN is a circular plasmid composed of double-stranded DNA molecules, which consists of the following two segments: CtrFd-Fnr segment and pL segment.
[0184] 8. Construction of E. coli V05
[0185] The recombinant plasmid pL-FDN and the recombinant plasmid pS-YZZ were simultaneously transformed into Escherichia coli V04 by the calcium chloride transformation method, cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml kanamycin and 50 μg / ml streptomycin, and the positive single clones were selected and sequenced for verification to obtain the recombinant Escherichia coli introduced with the recombinant plasmid pL-FDN and the recombinant plasmid pS-YZZ, which was named Escherichia coli V05.
[0186] IX. Construction of E. coli V06
[0187] The recombinant plasmid pS-YZZ was transformed into Escherichia coli V02 by the calcium chloride transformation method and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pS-YZZ, which was named Escherichia coli V06.
[0188] 10. Construction of E. coli V07
[0189] The recombinant plasmid pS-YZZ was transformed into Escherichia coli V04 by the calcium chloride transformation method and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pS-YZZ, which was named Escherichia coli V07.
[0190] XI. Construction of E. coli V08
[0191] The recombinant plasmid pS-YZZC was transformed into Escherichia coli V04 by the calcium chloride transformation method and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pS-YZZC, which was named Escherichia coli V08.
[0192] Example 2: Production of violaxanthin using recombinant Escherichia coli
[0193] The test bacteria were: Escherichia coli V05, Escherichia coli V06, Escherichia coli V07 or Escherichia coli V08 (all prepared in Example 1), Escherichia coli G01 or Escherichia coli BW25113.
[0194] 1. Inoculate the test bacteria into 200 ml of culture medium and culture at 30°C and 220 rpm until the OD 600nm The value is 0.7.
[0195] E. coli V05 was cultured in a liquid LB medium containing 50 mg / L streptomycin and 50 mg / L kanamycin. E. coli V06, E. coli V07 or E. coli V08 were cultured in a liquid LB medium containing 50 mg / L streptomycin. E. coli G01 or E. coli BW25113 were cultured in a liquid LB medium.
[0196] 2. After completing step 1, add L-arabinose to the system and make its concentration in the system 0.5 mM, then culture at 30°C and 220 rpm for 12 h, and then centrifuge at 8000 rpm for 10 min to collect the bacteria.
[0197] 3. Transfer the cells obtained in step 2 to the transformation medium (initial OD 600nmvalue was 20), and cultured at 30°C and 220 rpm for 18 h.
[0198] 4. After completing step 3, measure the light absorption value at 600nm, i.e. OD 600nm value.
[0199] Calculation method of dry cell weight (DCW): OD 600nm A value of 1 is equivalent to a DCW of 0.323 g / L.
[0200] 5. Detection of violaxanthin content using high performance liquid chromatography (HPLC)
[0201] After completing step 3, centrifuge at 8000 rpm for 10 minutes, collect the cells, wash with physiological saline, suspend in methanol-ethyl acetate at 4°C for 4 hours, filter with a filter membrane with a pore size of 0.22 μm, collect the filtrate, load the filtrate and perform high performance liquid chromatography. Methanol-ethyl acetate is obtained by mixing equal volumes of methanol and ethyl acetate.
[0202] HPLC system: LC 20A LabSolutions, Shimadzu Corp.
[0203] Chromatography column: Hypersil 1BDS C8 3μm (150×4.6mm) chromatography column.
[0204] Column temperature: 30°C. Detection wavelength: 450nm.
[0205] The mobile phase is liquid A or liquid B or a mixture of liquid A and liquid B; liquid A is methanol, and liquid B is composed of 7 parts by volume of methanol and 3 parts by volume of 0.1M ammonium acetate aqueous solution. Mobile phase flow rate: 1mL / min. Elution process: 0-1min, the volume fraction of liquid B in the mobile phase is 50%; 1-20min, the volume fraction of liquid B in the mobile phase is linearly reduced from 50% to 30%; 20-25min, the volume fraction of liquid B in the mobile phase is linearly reduced from 30% to 0; 25-32min, the volume fraction of liquid B in the mobile phase is 0; 32-35min, the volume fraction of liquid B in the mobile phase is linearly increased from 0 to 50%, and 35-45min, the volume fraction of liquid B in the mobile phase is 50%.
[0206] The violaxanthin standard was operated under the same chromatographic conditions as above to confirm the position of the target peak and to prepare a standard curve of the relationship between the violaxanthin content and the peak area of the target peak.
[0207] Substitute the target peak area of the test sample into the standard curve and calculate the violaxanthin yield per unit cell dry weight (mg / gDCW).
[0208] Five replicates were performed and the results were expressed as mean ± standard deviation. The results are shown in Table 1.
[0209] Table 1
[0210] Violaxanthin yield (mg / gDCW) Escherichia coli V06 7.07±1.09 Escherichia coli V07 15.25±2.13 Escherichia coli V08 3.38±0.62 Escherichia coli V05 20.14±2.66 Escherichia coli G01 0 Escherichia coli BW25113 0
[0211] Example 3: Construction of recombinant Escherichia coli
[0212] 1. Construction of recombinant plasmids pS-YZ and pS-YZC
[0213] 1. Prepare YZ fragment.
[0214] The YZ fragment is a double-stranded DNA molecule, which consists of the following segments from upstream to downstream: D1 regulatory element, crtY gene, D2 regulatory element, crtZ gene and TrrnB terminator.
[0215] 2. Prepare YZC fragment.
[0216] The YZC fragment is a double-stranded DNA molecule, which is composed of the following segments from upstream to downstream: D0 regulatory element, crtY gene, D0 regulatory element, crtZ gene and TrrnB terminator.
[0217] 3. Prepare the recombinant plasmid pS-YZ.
[0218] The recombinant plasmid pS-YZ is a double-stranded DNA circular plasmid consisting of the following two segments: the YZ segment and the pS segment.
[0219] 4. Prepare the recombinant plasmid pS-YZC.
[0220] The recombinant plasmid pS-YZC is a double-stranded DNA circular plasmid consisting of the following two segments: the YZC segment and the pS segment.
[0221] 2. Construction of E. coli Z04
[0222] The recombinant plasmid pL-FDN (constructed in Example 1) and the recombinant plasmid pS-YZ were simultaneously transformed into Escherichia coli V04 (constructed in Example 1) by the calcium chloride transformation method, and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml kanamycin and 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pL-FDN and the recombinant plasmid pS-YZ, which was named Escherichia coli Z04.
[0223] 3. Construction of E. coli Z01
[0224] The recombinant plasmid pS-YZ was transformed into Escherichia coli V02 (constructed in Example 1) by the calcium chloride transformation method, and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pS-YZ, which was named Escherichia coli Z01.
[0225] 3. Construction of E. coli Z02
[0226] The recombinant plasmid pS-YZ was transformed into Escherichia coli V04 (constructed in Example 1) by the calcium chloride transformation method, and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pS-YZ, which was named Escherichia coli Z02.
[0227] 4. Construction of E. coli Z03
[0228] The recombinant plasmid pS-YZC was transformed into Escherichia coli V04 (constructed in Example 1) by the calcium chloride transformation method, and cultured overnight at 37°C on a solid LB medium plate containing 50 μg / ml streptomycin. Positive single clones were selected and sequenced to obtain recombinant Escherichia coli introduced with the recombinant plasmid pS-YZC, which was named Escherichia coli Z03.
[0229] Example 4: Production of zeaxanthin using recombinant Escherichia coli
[0230] The test bacteria were: Escherichia coli Z01, Escherichia coli Z02, Escherichia coli Z03 or Escherichia coli Z04 (all prepared in Example 3), Escherichia coli G01 or Escherichia coli BW25113.
[0231] In step 1: Escherichia coli Z04 uses liquid LB culture medium containing 50 mg / L streptomycin and 50 mg / L kanamycin; Escherichia coli Z01, Escherichia coli Z02, and Escherichia coli Z03 all use liquid LB culture medium containing 50 mg / L streptomycin; Escherichia coli G01 or Escherichia coli BW25113 all use liquid LB culture medium.
[0232] The rest is the same as Example 2.
[0233] The zeaxanthin standard was operated under the same chromatographic conditions as above to confirm the position of the target peak and to prepare a standard curve of the relationship between the zeaxanthin content and the peak area of the target peak.
[0234] Substitute the target peak area of the test sample into the standard curve and calculate the zeaxanthin production per unit cell dry weight (mg / gDCW).
[0235] Five replicates were performed and the results were expressed as mean ± standard deviation. The results are shown in Table 2.
[0236] Table 2
[0237] Zeaxanthin yield (mg / gDCW) Escherichia coli Z01 15.23 Escherichia coli Z02 21.26 Escherichia coli Z03 10.17 Escherichia coli Z04 24.35 Escherichia coli G01 0 Escherichia coli BW25113 0
[0238] The nucleotide sequences of the primers used in the above examples are shown in Table 3.
[0239] Table 3
[0240]
[0241] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.
Claims
1. Recombinant E. coli is obtained by performing multiple modifications on E. coli; The multiple modifications include modification (a) and / or modification (b) and / or modification (c) and / or modification (e); Transformation (a): introduction and expression of mvaS gene, mvaE gene and mvk gene; Transformation (b): introducing and expressing crtB gene, crtI gene, crtE gene and idi gene; Transformation (c): introduction and expression of zep gene, crtY gene and crtZ gene; Transformation (e): Introduction and expression of pmk gene and mvd gene.
2. A method for constructing a recombinant Escherichia coli with improved violaxanthin production, comprising the following steps: performing multiple transformations on the Escherichia coli; The multiple modifications include modification (a) and / or modification (b) and / or modification (c) and / or modification (e); Transformation (a): introduction and expression of mvaS gene, mvaE gene and mvk gene; Transformation (b): introducing and expressing crtB gene, crtI gene, crtE gene and idi gene; Transformation (c): introduction and expression of zep gene, crtY gene and crtZ gene; Transformation (e): Introduction and expression of pmk gene and mvd gene.
3. The recombinant Escherichia coli according to claim 1 or the method according to claim 2, characterized in that: The plurality of modifications also include modification (h) and / or modification (i); Transformation (h): knockout of gor gene; Transformation (i): Knockout of trxB gene.
4. The recombinant Escherichia coli or method according to any one of claims 1 to 3, characterized in that: The plurality of modifications also include modification (d); Transformation (d): Introduction and expression of fd gene and fnr gene.
5. Use of the recombinant Escherichia coli or the method according to any one of claims 1 to 4 in the preparation of violaxanthin.
6. Recombinant E. coli is obtained by subjecting E. coli to multiple modifications; The multiple modifications include modification (a) and / or modification (b) and / or modification (k) and / or modification (e); Transformation (a): introduction and expression of mvaS gene, mvaE gene and mvk gene; Transformation (b): introducing and expressing crtB gene, crtI gene, crtE gene and idi gene; Transformation (k): introduction and expression of crtY gene and crtZ gene; Transformation (e): Introduction and expression of pmk gene and mvd gene.
7. A method for constructing a recombinant Escherichia coli with improved zeaxanthin production, comprising the following steps: performing multiple transformations on the Escherichia coli; The multiple modifications include modification (a) and / or modification (b) and / or modification (k) and / or modification (e); Transformation (a): introduction and expression of mvaS gene, mvaE gene and mvk gene; Transformation (b): introducing and expressing crtB gene, crtI gene, crtE gene and idi gene; Transformation (k): introduction and expression of crtY gene and crtZ gene; Transformation (e): Introduction and expression of pmk gene and mvd gene.
8. The recombinant Escherichia coli according to claim 6 or the method according to claim 7, characterized in that: The plurality of modifications also include modification (h) and / or modification (i); Transformation (h): knockout of gor gene; Transformation (i): Knockout of trxB gene.
9. The recombinant Escherichia coli or method according to any one of claims 6 to 8, characterized in that: The plurality of modifications also include modification (d); Transformation (d): Introduction and expression of fd gene and fnr gene.
10. Use of the recombinant Escherichia coli or the method according to any one of claims 6 to 9 in the preparation of zeaxanthin.
Citation Information
Cited By
Saccharomyces cerevisiae strain for de novo synthesis of fucoxanthine precursor neoxanthine and application of saccharomyces cerevisiae strain
CN120137810A
